Curogen Technology
Curogen is dedicated to becoming a milestone in the biotechnology industry and contributing to humanity’s health. The company focuses on developing first-in-class innovative therapeutics for incurable diseases, aiming to expand the horizon of medical research and harmonize with society. Their mission emphasizes creative research, open innovation, original technology development, and global competitiveness to cure humanity’s health.
Industries
Nr. of Employees
small (1-50)
Curogen Technology
16419 Suwon, South Korea, Sungkyunkwan University, Medical Building #6309
Patents
Pharmaceutical composition for diagnosing, preventing or treating liver cancer using SSU72 protein or a polynucleotide encoding the same
US-11918632-B2
View DetailsPharmaceutical composition for treating non-alcoholic fatty liver, non-alcoholic steatohepatitis, or hepatic fibrosis using Ssu72 protein or a polynucleotide encoding the same
US-11793862-B2
View DetailsMethod of preventing rheumatoid arthritis comprising administering polynucleotide encoding SSU72
US-10925933-B2
View Details
Pharmaceutical composition for diagnosing, preventing or treating liver cancer using SSU72 protein or a polynucleotide encoding the same
US-11918632-B2
View DetailsPharmaceutical composition for treating non-alcoholic fatty liver, non-alcoholic steatohepatitis, or hepatic fibrosis using Ssu72 protein or a polynucleotide encoding the same
US-11793862-B2
View DetailsMethod of preventing rheumatoid arthritis comprising administering polynucleotide encoding SSU72
US-10925933-B2
View DetailsProducts
Small-molecule candidate for inflammatory and autoimmune diseases (discovery)
A small-molecule program in discovery targeting inflammatory bowel disease, rheumatoid arthritis and multiple sclerosis; currently in discovery/preclinical development.
Multi-target therapeutic protein candidates (discovery)
Therapeutic protein programs designed to target multiple molecular targets for indications such as hidradenitis suppurativa, inflammatory bowel disease and multiple sclerosis; in discovery/preclinical stages.
Gene therapy candidate for NASH and HCC (preclinical)
Recombinant viral vector gene therapy candidate for nonalcoholic steatohepatitis and hepatocellular carcinoma with demonstrated efficacy in animal models; planned development with clinically characterized serotype vectors.
Small-molecule candidate for inflammatory and autoimmune diseases (discovery)
A small-molecule program in discovery targeting inflammatory bowel disease, rheumatoid arthritis and multiple sclerosis; currently in discovery/preclinical development.
Multi-target therapeutic protein candidates (discovery)
Therapeutic protein programs designed to target multiple molecular targets for indications such as hidradenitis suppurativa, inflammatory bowel disease and multiple sclerosis; in discovery/preclinical stages.
Gene therapy candidate for NASH and HCC (preclinical)
Recombinant viral vector gene therapy candidate for nonalcoholic steatohepatitis and hepatocellular carcinoma with demonstrated efficacy in animal models; planned development with clinically characterized serotype vectors.
Services
Virtual screening, library curation, docking analyses, MD simulations, pharmacophore analysis, hit extension and in silico lead optimization.
Design and execution of efficacy studies using established rodent disease models (psoriasis, IBD, NASH, HCC) with full reporting and data analysis.
One‑stop histopathology services including block/slide preparation, routine and special staining, IHC/IF/ICC, antibody optimization/validation, ROI imaging, quantitative image analysis and professional interpretation.
Consultation on experimental design, technology evaluation, assignment of study supervisors, contractual study management and final reporting for nonclinical programs.
Virtual screening, library curation, docking analyses, MD simulations, pharmacophore analysis, hit extension and in silico lead optimization.
Design and execution of efficacy studies using established rodent disease models (psoriasis, IBD, NASH, HCC) with full reporting and data analysis.
One‑stop histopathology services including block/slide preparation, routine and special staining, IHC/IF/ICC, antibody optimization/validation, ROI imaging, quantitative image analysis and professional interpretation.
Consultation on experimental design, technology evaluation, assignment of study supervisors, contractual study management and final reporting for nonclinical programs.
Expertise Areas
- Small-molecule drug discovery
- Therapeutic protein development
- Gene therapy preclinical development
- In silico high-throughput screening and computational chemistry
Key Technologies
- High-throughput virtual screening
- Deep-learning protein structure prediction
- Fragment-based drug design (FBDD)
- Molecular dynamics simulations
News & Updates
Curogen has been selected for a KDDF research grant for the 'Establishing R&D Ec…
Curogen has been selected for the 2024 Korea Drug Development Fund (KDDF) research grant.
주식회사 큐로젠은 22년도 전문연구요원 병역지정업체 선정 이후 꾸준히 병역지정업체로 선정되고 있습니다.
Medical Building #6309, Seobu-ro 2066, Jangan-gu, Suwon, S.Korea TEL. +82-31-299-6154
Bio Innovation Park Building 5F, 172 Magokjungang-ro, Seoul, S.Korea TEL. +82-2-6112-6900
Curogen has been selected for a KDDF research grant for the 'Establishing R&D Ec…
Curogen has been selected for a KDDF research grant for the 'Establishing R&D Ec…
Curogen has been selected for the 2024 Korea Drug Development Fund (KDDF) research grant.
주식회사 큐로젠은 22년도 전문연구요원 병역지정업체 선정 이후 꾸준히 병역지정업체로 선정되고 있습니다.
Medical Building #6309, Seobu-ro 2066, Jangan-gu, Suwon, S.Korea TEL. +82-31-299-6154
Bio Innovation Park Building 5F, 172 Magokjungang-ro, Seoul, S.Korea TEL. +82-2-6112-6900
Curogen has been selected for a KDDF research grant for the 'Establishing R&D Ec…